Will New Cardiometabolic Data on VK2735 Shift Viking Therapeutics' (VKTX) Obesity Treatment Narrative? [Yahoo! Finance]
Viking Therapeutics, Inc. (VKTX)
Last viking therapeutics, inc. earnings: 4/30 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.vikingtherapeutics.com
Company Research
Source: Yahoo! Finance
loss, prediabetes, and metabolic syndrome for patients treated with its dual GLP-1/GIP agonist VK2735 compared to placebo after 13 weeks. Importantly, the analysis showed that VK2735's effects on cardiometabolic health extended beyond weight reduction, with a substantial proportion of patients achieving normal glycemic status and improved metabolic profiles. We'll explore how VK2735's cardiometabolic benefits underpin Viking's investment narrative in the evolving obesity treatment landscape. Find companies with promising cash flow potential yet trading below their fair value What Is Viking Therapeutics' Investment Narrative? For anyone watching Viking Therapeutics, the big picture hinges on the success of its obesity drug VK2735, now in Phase 3, with both oral and injectable forms in the pipeline. The latest ObesityWeek 2025 data adds meaningful momentum by not only confirming sustained weight loss, but also highlighting improvements in metabolic syndrome and prediabetes tha
Show less
Read more
Impact Snapshot
Event Time:
VKTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VKTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VKTX alerts
High impacting Viking Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
VKTX
News
- Assessing Viking Therapeutics (VKTX) Valuation After Recent Share Price Recovery [Yahoo! Finance]Yahoo! Finance
- Viking Therapeutics (VKTX) VANQUISH-1 Trial Completes Early, H.C. Wainwright Retains Buy Rating [Yahoo! Finance]Yahoo! Finance
- Viking Therapeutics to Participate at the Piper Sandler 37th Annual Healthcare ConferencePR Newswire
- Viking Therapeutics (VKTX) Balances Rising R&D Costs With Clinical Progress: Is the Risk Worth the Potential? [Yahoo! Finance]Yahoo! Finance
- Viking Therapeutics (NASDAQ:VKTX) was upgraded by analysts at Zacks Research from a "strong sell" rating to a "hold" rating.MarketBeat
VKTX
Earnings
- 10/22/25 - Miss
VKTX
Sec Filings
- 11/5/25 - Form SCHEDULE
- 10/28/25 - Form 4
- 10/28/25 - Form 4
- VKTX's page on the SEC website